The opening months of 2025 have seen market swings, volatility spikes and ripening conditions for a bear market. Politics and geopolitics have taken central stage and will drive investment outcomes for sustainability portfolios for the remainder of the year and beyond. In this installment of our quarterly update on Macro Meets Sustainability, we argue that despite the noise emanating from Washington, in terms of concrete policy action, the euro area’s recent (fiscal) policy moves are the more significant market driver. We also underscore our view, outlined in several recent notes, that global inflation risks are rising while economic growth momentum is slowing, creating a stagflationary environment. The implication is that the rotation to defensive sectors and to euro area stocks has further to go.  

U.S. Noise and Euro Area Action

Contrary to mainstream media and financial pundits, our observation is that U.S. policy changes have underwhelmed so far in 2025; the biggest surprises and significant policy action have occurred in the euro area:

In the U.S., the daily headlines of federal firings, deportations, and tariff threats means the Trump’s administration occupies most of the space. However, what has actually been accomplished on any of these fronts?

In terms of DOGE, it’s difficult to know exactly how many layoffs have taken place but estimates of federal job separations in February were about 60 000, an insignificant number in an economy that employs over 160 million people. To be sure, the immeasurable loss of experience in federal institutions is lamentable and sows the seeds for challenges in the future. However, the impact on economic activity in the near term is likely to be very low.

Meanwhile, although much has been threatened, tariffs imposed on trading partners are so far only slightly more punitive than what occurred during Trump’s first term, which had little impact on overall global activity. The range of possibilities on what comes next is extremely wide, but a pattern has emerged whereby U.S. tariff barks have been worse than the bites.

Finally, while we continue to believe that over time, the level of illegal (and legal) immigration to the U.S. will be aggressively curbed, ICE is operating with the same budget that it had on Jan. 19. This suggests that it is highly unlikely that the government’s targets of over 1000 arrests per day are even close to being met; only the most migrant worker-dependent sectors like agriculture will feel the near-term impacts of current U.S. immigration policy.

In contrast, the threats and proclamations of the Trump administration have been sufficient to shake European policymakers out of their torpor as they seem to be working with renewed vigor. On Tuesday, the German parliament approved Chancellor Merz’s plan to spend up to €1 trillion in coming years on infrastructure and defense. EUR500B is earmarked for infrastructure and green initiatives. This massive spending deal means that just the infrastructure fund alone adds over 1% to GDP over the next decade, even without applying a fiscal multiplier (i.e. positive knock-on effect). Added on to this is the announcement in early March by Ursula von der Leyen that the new “ReArm Europe” investment plan will unlock a €150 billion loan scheme to help Member States invest in key military capabilities.

Our key takeaway is that while investors must stay attuned to possible impacts on global growth and financial markets stemming from the U.S., so far in 2025, realized policy activity has been more significant in Europe than in North America. This provides at least a partial foundation for why we expect the outperformance of euro area equities to continue for the next few quarters.

It’s Still The Economy, Stupid

Although it is well known that financial markets respond poorly to economic and policy uncertainty, the current instability in risk assets can not be solely attributed to uncertainty arising from Trump’s leadership style (described as “flooding the zone”). Indeed, U.S. economic growth was losing momentum well before Trump moved into the White House, and earnings expectations were also ratcheting down prior to Trump’s inauguration.

One very well-known and favored indicator is the economic surprise index, which tracks the strength of incoming data relative to expectations. In the U.S., the economic surprise index peaked in November and is now in negative territory, meaning that data is weaker than forecasted. In the euro area the indicator displays the opposite trend (data is surprising to the upside). The chart below shows the surprise indicator for the U.S.  

Of course, the above analysis is only useful in that it helps explain what has already happened. However, in the U.S. there is likely to be more months of negative surprises before an inflection point is reached because economic surprise indices tend to be mean-reverting and swing in regular patterns – it takes time for expectations adjust to economic reality.  

Beyond this, there are three reasons we expect that the environment for euro area stocks will support continued performance for the next few quarters:

1. More room for fiscal and monetary support outside of the U.S.: though it’s unknown to what extent Trump’s ambitions will translate into action, the direction of travel on virtually all of his stated plans translates to: more inflation and less growth in the near-term. We have written about the inflationary impulse in previous notes (for example, see “Food Fight: Policy’s Effect on Food Producers & Inflation”, February 13, 2025 and “Playing the Trump Card”, November 21, 2024) and the Fed’s updated FOMC projections yesterday are very much in line with our view. In plain language, Federal Reserve Chair Jay Powell acknowledged that further progress on inflation was likely to be “delayed for the time being”. The corollary is that the U.S. Federal Reserve may not have the leeway to loosen monetary policy given its 2% inflation target. Indeed, the OECD recently updated its inflation forecasts. With assumptions about future tariffs, the inflationary impact is strongest in North America.  

As discussed above, Germany is already forging a new path for fiscal policy and we expect other countries with the fiscal space will follow suit, whether it be in the form of relief to businesses to offset the tariff shock (as announced in Canada) or to raise defense spending.

2. Euro area sustainability stocks still trade at a discount relative to their U.S. counterparts. Euro area stocks have been comparatively cheap for years, but the recent divergence in price performance has done little to correct this gap. This is also true for the Sustainable Market Strategies’ sustainability universe. The average forward P/E for euro area stocks in our universe is 18 compared to 29 for the U.S.

3. The U.S. has Mag 7, but the euro area has defense stocks. The U.S. equity outperformance streak in 2023-2024 was without a doubt characterized by a strong tailwind emanating from the Magnificent 7 stocks and a bubble for everything artificial intelligence. China’s Deepseek helped to burst the bubble earlier this year. In contrast, we believe the prime candidate for a future “bubble” sector in the euro area is still in full swing. As we wrote in a recent note, “The European Defense Offensive: From Peace Dividend to War Premium”, the European Commission has recently unveiled an ambitious plan to mobilize approximately $840 billion to bolster the EU’s collective defense capabilities. There is a clear bias for European countries to invest in European defense companies, and despite the near parabolic rise in the biggest defense names, there are still several companies with moderate valuations that satisfy our strict sustainability criteria. But even for investors that do not wish to be long defense companies, the “euphoria” surrounding this sector will likely lift related stocks, especially euro area industrials. On this basis, just as the U.S. tech sector is becoming a drag on broad U.S. equity indices, the bull market in the euro area defense sector could boost European indices.

In sum, despite the fact that geopolitical tensions are emanating from the U.S. and onto the rest of the world, we expect that euro area stocks will continue to outperform.

Defensive Rotation Is Justified  

Stocks in defensive sectors like health care, consumer staples and utilities outperform when uncertainty is high and/or when recession risks are elevated because it is difficult to cut back on essential spending.

From a sustainability standpoint these sectors are often appealing because underlying products and services can create positive impact on individual lives. In recent weeks, we have written notes on two of these critical sectors – health care and food staples – and how sustainability investors should maintain a postive bias in this space despite needing to navigate the ongoing policy crosscurrents. Developments over the past few weeks only serve to strengthen our conviction. Interestingly, euro area stock markets tend to have a greater exposure to defensive sectors (healthcare is about 16% in the Eurostoxx 600 index versus 10% in the S&P 500), which also helps to explain some of the European outperformance in recent weeks.  

In times of economic uncertainty, investors turn to defensive sectors like healthcare. After all, people need medical care regardless of economic conditions.

But like almost all sectors in financial markets, healthcare is not immune to the volatility emanating from the new U.S. administration. Investors seeking stability in this impactful sector must navigate Trump’s desire to shakeup the U.S. healthcare system and Make America Healthy Again. Admittedly, this is a tall order since deciphering the signal from the noise during the Trump regime is difficult. However, of the eleven executive orders addressing aspects of U.S. health care, we believe there are three key areas to focus on:

In today’s Note, we consider these three political desires and how they affect the healthcare sector. We focus on drug producers, equipment makers and health insurance providers as these are the biggest categories within the healthcare sector and also the most at risk from policy changes. Investors looking to increase exposure to the health care sector should focus on companies with one or more of the following characteristics:

A. Drug Production: Favor “Small” Pharma, Chronic Disease Specialists

The appointment of Robert F. Kennedy Jr, as well as an executive order on February 13th, Establishing the President’s Make America Healthy Again Commission, clearly suggests the direction of policy travel: addressing the rising number of Americans – especially children – affected by chronic illnesses is a desired priority. After all, 90% of the U.S.’ $4.5 trillion in annual health care expenditures are for people with chronic and mental health conditions.

Concurrently, one of the few areas of the Inflation Reduction Act that has stayed in place under the Trump administration is the Medicare Drug Price Negotiation Program. The program was established to allow the Department of Health and Human Services (HHS) to negotiate maximum fair prices for certain high expenditure drugs and biological products. There are currently 25 medications that are subject to price negotiation with another 35 that will come to the negotiating table in 2028 and 2029 (a timeline is provided below); all were chosen because they are among the prescription drugs for which Medicare spends the most.

The first ten drugs identified for price negotiation have already settled: new prices come into effect in 2026 and the stock prices of companies affected have already digested the news. The negotiated price for the other fifteen drugs will only be announced in November 2025. Seventeen companies produce these 25 drugs, with Novo Nordisk, GSK and Astellas Pharma having the highest Medicare revenue from drugs selected for price negotiation. However, the financial impact on each company will ultimately depend on the extent of the negotiated price reductions.

Unsurprisingly, the list of drugs subject to price negotiations features many of the largest pharmaceutical companies. In the table below, we highlight the top five players by market share in each of the five most common chronic illnesses. Note that while for some illnesses like cancer and Alzheimer’s disease, there is a more diversified market (the top five players account for less than half of total market share), for other diseases (arthritis, diabetes) only a handful of companies dominate accounting for over 75% of the total market shared.

Interestingly, the table shows just how big “big pharma” really is. Companies like Pfizer and Johnson and Johnson are among the top players in not just one, but often two or three chronic illness medications. Moreover, they often compete in many other (non-chronic disease) markets; 40% of Pfizer’s revenues are derived from infectious disease medications, and over 20% of Johnon & Johnson revenues are from vaccines.

One could argue that the diversified nature of big pharma’s activities means these companies are well protected from a specific risk or disruption in any one pharmaceutical line. We believe that in the current environment, the opposite is true: a government set on bringing down prices will continue to target the biggest players first.

Therefore, when seeking out defensive health care companies with exposure to chronic illness remedies, we look for:

By applying the above criteria, we find twelve companies in four chronic disease segments (cardiovascular, oncology, endocrinology, and neurology); we expect that ongoing drug price negotiations and President Trump’s push for greater transparency in pharmaceutical price setting will foster a more competitive price environment for smaller companies. These players also have potential as acquisition targets by larger pharmaceutical companies.

Looking at financials for these companies, we favor United Therapeutics (UTHR US), Ipsen (IPN PA) and Neurocrine Biosciences (NBIX US).

United Therapeutics is the only company identified in cardiovascular drugs. The company is specialized in drugs treating hypertension. It boasts strong margins, sales growth and a fair valuation. Despite record revenues in 2024, a slight miss on latest earnings report sent the stock price lower in late February – presenting a compelling entry point.

From the oncology segment, Ipsen is appealing: in addition to having over 70% of its revenue generated from cancer treatments, its remaining revenue sources also stem from non-communicable disease treatments (neurology medications, 19% and OTC drugs, 8%). The company’s relatively lower growth and margin profile suggest a potentially more stable investment than high-growth biotech plays. We like it for this and the associated low beta. Alternatively, the U.S. oncology company Exelixis, demonstrates higher sales growth and a stronger margin while maintaining a low beta, making it a more dynamic alternative within the space.

Within the neurology drugmakers, Neurocrine Biosciences has strong sales growth and profitability, at a reasonable valuation, with lower debt than some of its peers.

 

B. Healthcare Insurance: Avoid the Giants

The major U.S. health insurance providers, aka “Big Health”, are also at risk from policy efforts to crack  down on healthcare costs. Their vertically integrated business models, encompassing Pharmacy Benefit Management Services (PBMs), patient care, drug distribution and other health care services, make them particularly vulnerable to systemic changes.

Cuts to Medicare and Medicaid could reduce revenues from government-managed plans – especially Medicaid, where low-income individuals are unlikely to convert to private plans. Moreover, price transparency reforms threaten profits in patient care, drug sales and PBMs. PBMs have been directly called out by Trump for their role in higher drug prices, he has threatened to “knock them out.” UnitedHealth, Cigna, CVS and Elevance account for virtually all (99.8%) of the PBM market according to FactSet data. While cuts to government-supported health coverage will face some resistance, broad dissatisfaction with the U.S. healthcare system means efforts to curb high prices will have bipartisan support, meaning there is greater likelihood that those initiatives pass.

There are some health service providers already offering an alternative approach. So-called “value-based” healthcare incentivizes patient outcomes over volume of tests, prioritizing quality over quantity and assessing value through the cost of treatment for the achieved health outcome. These companies have a competitive edge that puts them ahead of potential regulatory changes. Privia Health (PRVA US) is one such company. It partners with physicians, using technology and offering administrative support to improve patient experience and reduce unnecessary costs. Other value-based insurers like Alignment Healthcare and Clover (both also over US$1 billion in market cap) have had strong stock performance but have reported negative earnings in the past few years.

C. Healthcare Equipment: What Domestic Production?

Medical equipment makers face limited risks from healthcare policy changes but nonetheless remain exposed to trade tensions and geopolitical shifts: U.S. tariffs could increase costs for multinational manufacturers, creating advantages for domestic producers. Additionally, retaliation to tariffs, like China’s recent ban on Illumina’s gene sequencers, highlights the possibility of tit-for-tat trade wars in the sector.

Readers of our work know that healthcare equipment, especially those focused on an aging population, is one of our favored health care sub-sectors (for example, “Grandpa’s Gadgets: Healthcare Devices for Increased Longevity”, June 22, 2024). Normally, companies that specialize in joint replacement and orthopedic products, vision and hearing solutions as well as diagnostics and treatments for chronic illnesses are excellent outperformance candidates during bear markets and the recent correction is no exception, as shown in the chart below. Unfortunately, however, the trade backdrop now obfuscates the outlook.  

The main lobby group for medical device makers, Advamed has already sought an exemption from Trump’s tariffs, saying that tariffs will devastate the industry. Indeed, about 70% of U.S. marketed medical devices are manufactured solely outside of the U.S., making the industry highly reliant on foreign production.

Whether the industry can negotiate a tariff carve-out is an open question, although there is a positive precedent. In 2018, Advamed effectively lobbied the Trump government and was able to severely limit the number of medical devices that were subjected to Trump’s China tariffs at that time.

In the table below, we provide a shortlist of medical device manufacturers that have strong tailwinds to their businesses, though long positions should only be activated if tariff carve-outs occur. Note that compared to pharmaceutical companies, equipment makers on average exhibit higher valuations and relatively lower beta. In particular, Edwards Lifesciences, Abbott Laboratories and Danaher stand out, combining high R&D investment, strong profitability, and solid sales growth with manageable debt.

Almost two years ago, we wrote what was then a controversial note about the role of defense companies in sustainable investing (see Defending the indefensible? An ESG perspective, May 11, 2023). Fast-forward to today, and this topic has become much more accepted, though still not quite mainstream.

In our previous note, we argued that a subset of the defense sector—specifically what we called the “European Defense Specialists” as opposed to the “American Defense Primes“—should be considered by sustainability-minded investors. Our thesis was based on two key factors: European defense companies demonstrate significantly stronger governance than their American counterparts, and European defense expenditures were poised for massive increases. This strategy has performed exceptionally well, with the SMS European Defense Specialists Basket dramatically outperforming both American Defense Primes and the S&P 500 since our May 2023 publication.

The End of Pax Americana

Recent geopolitical developments, including the Oval Office showdown between Zelenskyy, Trump, and Vance that led to the immediate freezing of all U.S. military support to Ukraine, only strengthen our thesis. What we're witnessing is essentially the end of the post-Cold War "peace dividend" era. For decades, European nations comfortably operated under the Pax Americana security umbrella, maintaining modest defense budgets while focusing on social spending and economic integration. This convenient arrangement—Europeans handling "soft power" (diplomatic influence, cultural appeal, economic incentives, and humanitarian aid) while America provided "hard power" (military might and security guarantees)—is now being fundamentally reconsidered.

Prior to 2022, only the UK, Poland, and France among major European powers were approaching or exceeding NATO's 2% target. Faced with the stark realization of their strategic vulnerability, European nations have been forced to step up.

The ReArm Europe Initiative

Earlier this week, the European Commission unveiled an ambitious plan to mobilize approximately $840 billion to bolster the EU's collective defense capabilities. This plan, dubbed "ReArm Europe," aims to provide European countries with the financial resources to modernize their armies, enhance their collective defense systems, and increase support for Ukraine.

The initiative includes a new fund worth more than $150 billion to support EU members' defense investments, while simultaneously relaxing the bloc's debt rules (effectively the "debt brake" to allow for higher defense spending). Additionally, the EU plans to leverage profits from sanctioned Russian assets (approximately $200 billion held in Europe) to help finance military assistance to Ukraine. While some, like President Zelenskyy, have floated the idea to seize and redirect these $200 billion towards security, France's finance minister has expressed opposition to this mechanism as these are Russian central bank assets and are protected by international banking agreements.

 

The Global Defense Spending Shift

The chart below illustrates the dramatic shift in the global balance of defense spending from 2011 to 2023. The United States has experienced a steady decline in its proportion of global defense spending, dropping from over 50% in 2011 to just 37.7% by 2023. Even in absolute terms (using constant 2022 USD), U.S. spending fell from nearly $1 trillion in 2010 to approximately $880 billion in 2023—a reduction of 12%.

Conversely, Europe (including the UK) has demonstrated remarkable growth, particularly in recent years. From 2011 to 2021, European defense spending as a percentage of the global total increased modestly from 17.9% to 19.8%. However, 2022-2023 showed dramatic acceleration, with Europe's share jumping to 24.4% by 2023—a clear response to the radically altered security environment following Russia's invasion of Ukraine. With the implementation of the ReArm Europe initiative, Europe's defense expenditures could represent over one-third of global defense spending within the next few years.

 

A More Sophisticated Screening Approach

These developments reinforce our conviction to focus on European Defense Specialists rather than American Defense Primes. We've expanded our analysis to include several additional critical factors:

  1. Allied Revenue Alignment: We assess the proportion of revenue derived from NATO and other allied nations, aiming to minimize exposure to companies with significant revenues from potentially misaligned or authoritarian regimes.
  2. Government Independence: We evaluate the percentage of each company owned by governments. Generally, we favor greater independence from government control to maximize innovation potential and governance quality.
  3. R&D Investment: We analyze R&D expenditure as a percentage of revenue. Modern warfare demands constant technological advancement—companies that fail to innovate today will be irrelevant tomorrow.
  4. Strategic Defense Orientation: We focus on companies specializing in technologies and systems designed primarily for defensive purposes—such as air defense systems, cybersecurity solutions, and intelligence platforms—rather than offensive-oriented activities like armored assault vehicles, strike missiles, and tactical combat systems.

Based on this multi-factor approach, six companies stand out as meeting most of our criteria (highlighted in green in the table above).

Unsurprisingly, all six companies have performed exceptionally well since Russia's invasion of Ukraine three years ago. Even the weakest performer in our selection managed to outperform the S&P 500 by a factor of three. However, the performance disparities within the group are notable and raise a critical question: Can this level of outperformance be sustained?

To assess whether these companies can maintain their momentum or if “laggards” might catch up, we look at forward valuations using 12-month price-to-earnings ratios.

While Saab and Leonardo predictably command higher valuations given their remarkable performance runs, what's truly surprising is that despite their extraordinary performance, their P/E ratios remain below 35x—relatively reasonable for companies experiencing such dramatic growth.

Nevertheless, considering the parabolic trajectories of Leonardo and Saab, a prudent alternative strategy would be to shift focus toward the "second wave" of European Defense Specialists. These companies—Thales SA (HO-FR), BAE Systems plc (BA-GB), Indra Sistemas SA (IDR-ES), and QinetiQ Group plc (QQ-GB)—stand to benefit substantially from the recently announced ReArm Europe program and have yet to experience a dramatic valuation expansion.

The global fertility rate has dropped from around 5 children per female in the 1960’s to a little above 2 now. It is expected to fall below replacement level (2.1) over the next quarter-century. The map below shows where fertility remains above the replacement level: Africa, the Stans (former Russian Republics like Kazakhstan and Uzbekistan plus Afghanistan and Pakistan) and a few countries in South America and elsewhere. It also highlights countries with abnormally low fertility rates like South Korea (under 0.6) and China (1).

The table below lists reasons why fertility rates have fallen so much; from urbanization, lifestyle, policy and biology (contraception improvements, pollution, biological age limits and declining sperm counts). It is difficult to imagine a rapid reversal of those factors.

You Cannot Fake Population Growth

One of the main implications of slower population growth is the impact on real economic growth. Take Scott Bessent’s new 3-3-3 target, which aims for a 3% deficit, 3 million barrel/day of extra US oil production, 3% real GDP growth).  Real GDP growth relies on a combination of population growth and productivity growth. In order to achieve 3% real GDP growth, productivity will need to surge to offset the stagnation in the working age population. On the deficit side, an older population is a challenge to spending reductions.

The map below highlights how populations around the world are expected to evolve over the next five years. Most of Europe, Russia, China, Japan and South Korea are expected to have shrinking population whereas other developed economies are expecting limited growth.

Slowing population growth will also be accompanied by a much older population with higher healthcare spending. Considering that in the United States, healthcare expenditures already represent close to 20% of GDP , any productivity improvement in the sector will have to be considered for healthcare to stop growing as a percentage of the economy.  

The chart below shows that the peak growth in the elderly population is happening now while overall population growth is slowing. Common discourse implies that we are getting older, but you never hear that we are right in the middle of the peak intensity on a global basis.

A growing elderly population should benefit healthcare companies. The table below highlights companies focused on improved healthcare productivity within our sustainable company investment universe; we expect a growing market for their products and services.

The chart below highlights each company’s stock performance since 2019. As we can see, there have been winners and losers compared to the S&P 500 without a clear trend for the group as a whole.

Senior Spend on Pills

An older population generally requires more health care which puts a strain on public finances and risks triggering intergenerational conflicts; the overwhelming older population will vote to maintain subsidized health services and the young will want better after-tax compensation. The map below illustrates the anticipated evolution of the population for people older than 72; there will be increases in the senior population everywhere in the world over the next five years,  except for that little red dot on the map in Timor-Leste where life expectancy is just 69 years old .

The growing number of elderly (72+) will mean increase demand for medication. The table below shows pharmaceutical companies from our sustainable investment universe with solutions for a global population that is living longer.

Just like the performance chart for healthcare productivity companies, there have been winners and losers compared to the index. The two winners, Eli Lilly and Novo Nordisk, have mainly won because of their obesity pills that are not targeting elderly people, at all. As a result, there could be a catch up from the other companies based on growing demand for their products.

Senior Lodging is another segment that will have growing demand. The table below highlights sustainable companies providing senior lodging.

Real estate has suffered from higher interest rates since the pandemic. As we can see, performance for the group has been poor on an absolute and relative basis. Unlike other parts of real estate, like office that has oversupply, senior lodging should have better pricing power in the future.

Smaller Market for the Smallest

On the other hand, the large drop in fertility rate is leading to a totally different picture for children. As the map below shows, most countries will experience a large drop in child populations over the next five years. China and South Korea are among the places where the percentage decline is highest, while increases in the number of children will mainly occur in Africa. Considering the large increases in elderly and the large drop in future workers (children) over the next decade, the incentive to increase  immigration, especially for skilled-care workers, should rise.  

Companies that focus on products and services for children will face headwinds. The following table shows companies that will need to cope with a globally shrinking children market. Those companies are not negative from a sustainability basis, but we believe investors should be aware that demand for their products could fall.

The stock performance of these companies has been lacklustre other than Build-a-Bear which has boomed.

One of our high-conviction calls for the coming decade is the high likelihood of strong, sustained food inflation. To put it simply, absent a massive productivity surge, it is unlikely that farmers will be able to feed us the low-cost, high caloric diet we have become accustomed to, especially as climate change wreaks havoc with growing seasons and creates the conditions for ever more animal viral outbreaks.  

Beyond this base case, a series of policy developments are unfolding in America that hold the potential to disrupt food supply chains. Immigration, tariffs, diminishing government oversight and particular cabinet picks are sparks that have been lit by Trump in 2025 and are on the cusp of unleashing a surge in food prices. Today’s note explores these sparks and what it means for publicly traded food companies.

Implications of Immigration

During his first days in office, Trump took action on immigration as promised during the campaign. The crackdown on inhabitants without legal status is expected to have significant consequences for American farmers. USDA data show that nearly half of the country’s crop farm workers are unauthorized to be in the United States (crop farm workers accounted for 75% of U.S. employment in agriculture in 2023).

Impacts from immigration will also be felt in the livestock sector, which makes up the balance of agricultural employment. Not surprisingly, meat-processor Tyson highlighted immigration policy as a source of uncertainty during the company’s latest earnings call.

The H-2A visa program for farmers to hire foreign agriculture workers temporarily could be seen as a workaround to the deportation issue. But the program’s future under Trump remains unclear; it was mentioned in Project 2025 leading some to anticipate a more challenging approval process. The popularity of these visas (see chart below) underscores the shortage of farm labor in the U.S.; certifications nearly tripled in the last decade. Still, this program is an expensive option - farmers must cover transport, shelter and meal costs for employees in addition to wages that are tied to state minimums.

Investment in automation could be one response to higher labor costs, benefitting companies like Deere, but we remain cautious. Depressed commodity prices, relatively higher interest rates and ongoing tariff uncertainties will make farmers hesitant to spend on equipment upgrades. Subsidies could provide relief (the farm bill has been up for renegotiation since 2023), but increased spending appears challenging under an administration so focused on budget cuts. Furthermore, farm equipment-makers face their own tariff risks: China has targeted farm equipment in its retaliation to U.S. tariffs and last fall Trump threatened a 200% tariff on Deere over the company’s Mexico-based production.

Troubles from Tariffs

On February 4th, Trump imposed a 10% blanket tariff on all products imported from China and is set to impose 25% on Canada and Mexico beginning March 1st. Meanwhile, he also is threatening further duties on European imports. Unless loopholes are created, the food sector will not come out unscathed.

About 15% of total food consumed in the U.S. is imported and the vast majority of this comes from China, Mexico and Canada. In the chart below, we show the impact on CPI food inflation. We assume 15% of the total food basket is slapped with a 25% tariff, while the rest remains at the 2024 annual rate of 2.2%. In this scenario, food price inflation will average close to 6% over the next year, simply due to the tariff effect. With the exception of the COVID period, one has to return to the 1990s to see this level of U.S. food inflation.

Note, this could be a conservative estimate of food inflation, since it does not account for the rising prices of many other input costs also subject to tariffs. For example, the 25% tariff applied to all aluminum imports will affect the cost of packaging (aluminum cans). And as noted in the section below, the cost of fertilizers is a major concern.

As the chart below shows, about one quarter of all fertilizers used in the U.S. are derived from potash. Canada supplies virtually all of the potash used as fertilizer in the U.S. Reliance on foreign sources of nitrogen is considerably less (between 6%–13% of total nitrogen consumption has been imported since 2020). Finally, phosphate imports represent between 6-16% of total phosphate, virtually all of it sourced from Peru and Morocco (countries that are not yet in the crosshairs of Trump).

The bottom line is that Trump’s 25% blanket tariffs will affect about one quarter of all fertilizer used in the U.S., which risks being another important source of inflation to the extent that this input cost is inevitably passed on to end food prices.

Loosey Goosey Regulation (Avian Flu)

Anyone reading American press will know that the price of eggs has become a sore point for many consumers. Avian flu (a.k.a. H5N1 virus) has caused the price of eggs to skyrocket, as 20 million egg-laying chickens have died from the virus in the past quarter.

Unfortunately, it is extremely unlikely that the U.S. H5N1 crisis will end soon. The outbreak is in part a government failure; there is a large consensus view that the USDA did not act swiftly and aggressively enough to stem the virus when it could and it is unlikely a coincidence that other North American jurisdictions have had far more success controlling outbreaks. It is an open question whether the new head of the USDA (Brooke Rollins) will implement policy to stem the animal losses.  

Perhaps ironically, some of the biggest American egg producers have seen their profitability and stock price benefit from the outbreak. The two largest publicly traded egg producers are Cal-Maine Foods (CALM US) and Vital Farms (VITL US). Both have seen their stock price skyrocket in the past years, but for sustainability investors looking to get long, only one of these companies merits attention. CALM US has a terrible environmental track record and overall low rankings in CSRHub scores. Moreover, and probably not a coincidence, one reason why the company has been profitable over the past year is because they are a beneficiary of generous H5N1 indemnities: when outbreaks happen, the federal government pays to compensate farmers for the culling of birds and sanitizing of facilities; Cal-Maine has been one of the largest recipients of this aid.

Conversely, VITL has largely avoided avian flu outbreaks over the past three years and is routinely ranked highly for more sustainable practices. Investing in egg stocks at this juncture is a high-risk endeavor, but for investors that like the odds, VITL US is our favored play.

Cabinet Picks Stir the Pot

Although picked for Health and Human Services Secretary, nominee Robert F. Kennedy Jr. (RFK Jr.) will have important implications for food and ag. This role has limited authority over agriculture policy, but does oversee the Food and Drug Administration which regulates food safety. RFK Jr. has been vocal in his criticism of ultra-processed foods and pesticides use. As part of the Make America Healthy Again campaign, RFK Jr. has pledged to take on Big Food.

Weed and pest management has become a key component in agricultural production. Globally, the U.S. is second only to Brazil for total use of pesticides. The charts below show the pesticides use per hectare of farmland (kg/ha).

Over the last decade, pesticide use per unit of land has stabilized in Europe but continued to grow in the United States. This reflects stricter regulations in the EU, but also the dominance of pesticide-intensive crops such as corn and soybeans in America.

Given the environmental and public health risks associated with heavy pesticide use, stronger regulation is not a bad thing. With RFK Jr. selected by a Republican president known for strong-arming, pesticide regulation could gain more conservative support than in the past. However, this would present an enormous hurdle for the agri-science industry (see our note “Agriculture’s Addiction Problem”, September 1, 2022). Curtailing pesticide use would, all things equal, reduce crop yields (food supply) and (once again) put upward pressure on prices.

How to Invest

High food price environments often favor the major food processors like General Mills, Campbell’s, Hershey’s, etc, since they also have the ability to pass on higher input costs in (i.e. have pricing power). Indeed, these companies outperformed the broad market in 2022 when COVID induced supply chain delays caused a spike in food inflation and they also outperformed during the 1970s’ food inflation spikes.

However, as readers of our previous work will know, investing in these companies is no easy task for investors who prioritize sustainability (please see “No Free Lunch: Challenges and Opportunities for Engagement in the Food Supply Chain”, March 7, 2024). Controversies are common (greenwashing, anti-competitive practices) and the holding of subsidiaries that often focus on unhealthy snacks makes these companies often unappealing.

For sustainability investors looking to get long food manufacturing business to position for the likely wave in food price inflation, one approach is to hold a broad basket of the major food companies, and exclude the companies that contribute most to the sweets and snack foods category: Pepsi Co., Mondelez, Hershey, Nestle, Barry Callebaut and Kellanova (the latter is the snack division spun off from Kellogg’s).

Note that in our 2025 Investment Playbook, we highlighted Mondelez and Pepsi as two short candidates based on the premise that they do not fit RFK’s view of healthy food. These companies have already lost value in the run up to his confirmation.

With these exclusions in place, the below table highlights some of the food companies with good sustainability scores that have a lower contribution to the unhealthiest aisles in the grocery store. Of course, to be taken with a grain of salt, while these companies have less revenues from snacks and sweets, some of their products are still deemed unhealthy.

From a financials perspective, Kraft Heinz has higher margins, a lower valuation and positive EPS growth. General Mills also exhibits higher profitability and better growth. Unsurprisingly for consumer staples, all of the companies have forward P/E valuations below the SP500.

To convince yourself that six months can fundamentally reshape market narratives, look no further than the dramatic reversals in political consensus or the stark trajectories of pharmaceutical giants Novo Nordisk and Eli Lilly. The meteoric rise and subsequent recalibration of GLP-1 drugmakers’ valuations offer a compelling case study in market psychology and pharmaceutical sector dynamics. Much like NVIDIA’s AI-driven surge, investors initially viewed obesity treatment approvals as an inflection point that would propel these companies into sustained upward trajectories. However, the narrative has proven more complex, with Novo Nordisk’s stock retreating 45% from its summer 2024 peak and Eli Lilly declining 25% from its highs. This correction reflects a market coming to terms with the practical challenges of scaling revolutionary treatments. In this note, we examine the factors behind this shift in sentiment, analyze the operational and market hurdles facing the industry, and explore emerging opportunities in the evolving GLP-1 landscape.

The recent pullback in obesity drug stocks can be attributed to several key factors, but primarily centers around access and pricing challenges. Since 2021, there has been a meteoric rise in the adoption of GLP-1 drugs: semaglutide prescriptions in the U.S. jumped from about 2 million adults in 2021 to an estimated 15 million in 2024, representing over 10% of eligible patients. However, this rapid growth has begun to face headwinds in penetrating the remaining addressable market, largely due to insurance coverage constraints.

In the U.S., insurance coverage remains fragmented and restrictive:

The political landscape adds another layer of uncertainty. Robert F. Kennedy Jr., Trump’s nominee for Health and Human Services Secretary, has historically criticized weight-loss medications, arguing they create dependency rather than addressing root dietary issues. However, his recent statements suggest a potential softening of this stance, acknowledging GLP-1s’ role in chronic condition management and indicating openness to selective coverage.

Further complicating the outlook, Ozempic and Wegovy’s inclusion in the IRA’s drug price negotiation program could substantially impact U.S. pricing of these drugs. Pricing disparities are evident internationally: monthly Wegovy prescriptions cost $140 in Germany and $92 in the UK, versus $1,349 in the U.S. This gap highlights the potential magnitude of price adjustment under government negotiations, similar to what we observed in the insulin market (as detailed in our note (“Basic Instinct: The Insulin Profit Machine”, September 22, 2023).

The competitive landscape is also evolving rapidly. While Novo Nordisk and Eli Lilly command a formidable first-mover advantage, their competitors are aggressively accelerating development programs to capture share in this lucrative market. The battleground is increasingly centered on accessibility and affordability, with particular emphasis on oral formulations that could dramatically expand the addressable market (current GLP-1 medicines are administered by injection). Several promising candidates are emerging.

Market leadership appears secure in the near term, with Novo Nordisk and Eli Lilly commanding nearly half of the industry's development pipeline. The competitive moat is substantial: major pharmaceutical companies like Roche, Pfizer, AstraZeneca, and Amgen lag several years behind, with meaningful competition unlikely before 2028/2029 once accounting for commercial-scale manufacturing ramp-up.

The most compelling competitive threat is Structure Therapeutics (GPCR US). Their oral GLP-1 candidate has demonstrated promising early results and, while still 12-24 months from potential commercialization, represents the most advanced oral formulation in development. Their progress warrants close monitoring as oral administration could revolutionize market dynamics.

Patent expiration presents another frequently cited risk, though the timeline suggests limited near-term impact:

However, the complexity of manufacturing GLP-1 drugs provides an additional barrier to generic competition. Unlike small molecule drugs, biologics, which are developed from living organisms, require sophisticated production capabilities that few manufacturers possess. This complexity, combined with the extensive regulatory requirements for biosimilars, suggests that generic competition may evolve more gradually than historical pharmaceutical patent cliffs would indicate.

Despite these challenges, forecasts suggest the weight-loss drug market is poised for exponential growth—fueled by rising demand, expanding applications, and continued innovation.

The transformative potential of GLP-1 drugs extends far beyond obesity treatment. Recent clinical evidence suggests these compounds may revolutionize the treatment of various addictive behaviors by modulating reward pathways in the brain. Their ability to curb food cravings appears transferable to other dependencies, including tobacco, alcohol, and even opioids, opening entirely new therapeutic frontiers.

Perhaps most intriguingly, emerging research indicates promising applications in neurodegenerative conditions, particularly Alzheimer's disease. The connection lies in the brain's glucose metabolism—a critical factor in cognitive function that becomes impaired in Alzheimer's patients. GLP-1 drugs' ability to regulate glucose metabolism could potentially slow or alter disease progression, representing a novel approach to this devastating condition.

The recent market correction in Novo Nordisk and Eli Lilly shares appears overdone, presenting a compelling entry point into what we believe is still the early innings of a transformative healthcare trend. Both companies have demonstrated their ability to develop and commercialize life-changing medications, and their current valuation post-correction offers a more attractive risk-reward proposition.

While we maintain high conviction in both companies' leadership positions—earned through pioneering innovation and sustained by significant R&D investment—investors seeking broader exposure to the theme might consider diversified vehicles such as the Roundhill GLP-1 & Weight Loss ETF (OZEM US).

As it has become a tradition at SMS, December is the time when we take a step back and look at our investment calls of the past year – mostly to help us identify our own cognitive biases. This year’s review happens at a time when 2024 will be the very first year when the world will have breached the 1.5 degree Celsius of warming above 1900 levels – despite countries’ commitments (including those of the investment community) made at the Paris 2015 Climate Agreement.

With this in mind, today’s note looks at our past performance – the good, the bad and the ugly. We first look at the performance of our 2024 new year’s investment calls and then look at the performance of our various investment themes and universe. Finally, we look at trades that we still have in play which we’ve researched in the past few months and which could still have some legs in 2025. Today’s note sets the table for our next publication on January 9th which will outline our investment views for 2025. We wish our reader a very happy holiday season.

  1. A Look at Our 2024 Early Calls

We had five main views at the outset of 2024 (see our note “Investment Trends in 2024: Bounce Back for Sustainability”, December 14, 2023): 1) Long Industrials over Consumer Discretionary, Long Uranium and Nuclear (stocks like Cameco; 2) Toe-dip into sustainable infrastructure and renewable energy/energy efficiency (e.g., MSCI Alternative Energy) when rates start to abate, 4) Long North American carbon markets and 5) Short “Buy Now, Pay Later” stocks (such as Affirm).

In retrospect, these calls have performed quite well – at least until the election of November 5th. Except for Energy Efficiency, the sustainability complex reacted positively to a lower yield environment in the first three quarters of 2024 – only to be clobbered in Q4 in the lead up to and the outcome of the election – and its accompanying 60 bps upswing in yields. Trump was clearly a ‘known unknown” type of event for the sustainability complex, which was compounded by the expectations that the new Administration will bring significant changes to the Inflation Reduction Act and its suite of pro-climate policies.

One of our favorites – yet unprofitable – calls of 2024 was to be long North American regulated carbon allowances. This proved a money-losing proposal – where we bet too early on a recovery in California carbon prices coming from trends such as 1) increased demand for energy, 2) re-industrialization and 3) the reshoring of the U.S. Economy. We are still waiting for a bounce in North American carbon prices.

2) SMS Thematic Performance

Turning to our aggregate thematic performance, the first consideration is that our average long and short call of 2024 (calculated since the note was published on an equal-weighted basis) made a YTD return just shy of +4%, which compares palely to the S&P return of +27% (in USD) and +33% for the NASDAQ YTD. Our Tech calls proved the most performing, closely followed by those in sustainable infrastructure, while sustainable transportation and transition materials where our worst themes.

This performance underlines the subpar performance of most sustainability funds throughout 2024. This happens amid a context where most ESG/sustainability/impact funds have continued to underperform “normcore” benchmarks by a margin. To this point, it’s hard to make a buck when your long investment universe tanks and when your short investment universe is on a tear. This was the problem of many sustainable investors the past year.

This also justifies the current conversation about what would be the appropriate benchmark for sustainability-focused investors – especially those who are serious about moving capital towards a more sustainable world – without losing face with their stakeholders. That said, readers should be (conveniently) reminded that past performance is not indicative of future results.

Looking at the performance of our long (based on the date at which our note was written), one sees that none of our themes matched the stellar performance of the all-powerful US market.

Looking at our shorts – which were incredibly hard to do when markets are up by so much – our average call yielded a -6.4% performance (our shorts actually went up in price), mostly driven by Food Sustainability and Transition Materials. Considering the impressive performance of markets so far, one could say that the fact that our short calls went down by just -6.4% is a testament to our ability to pick companies in our short themes.

3) SMS Universe – Mostly Red, Not Much Green

Finally, looking at SMS’ investment Long/Short universe of approximately 700 companies out of the MSCI All Country World Index, one also sees how hard 2024 was. Overall, our long universe went up by 13% (that’s half the performance of the S&P 500 YTD), while our short universe went up by 20%. In this context, it’s been hard to build outperforming portfolios.

4) Selection of calls that worked in 2024 and still have some legs for 2025

a) Short Temp Staffing

We first published on temp staffing agencies on January 18, 2024 (Temp Staffing Agencies: Minimum Pay & Minimal Returns). As labor markets started to show some slack on both sides of the Atlantic, we saw an opportunity to take short positions on stocks such as Adecco, Robert Half and Manpower. Temp staffing firms are notorious for underpaying their staff and offering less-than-market working conditions to their employees – which are often the first to be let go when sales sour. This play was very timely.

b) Long Engineering Services – especially those active in sustainability fields

Engineers can be boring (SMS has some on its team) – but they can sure deliver – as per SMS equal-weighted Engineering index this past year which beat the NASDAQ index. In fact, SMS wrote on engineering firms last August, whose business lines can be closely related to sustainability and climate adaptation – and which should continue to benefit from Trump’s America first policies (see our August 19, 2024 note, “US Election Color Wheel: Spotting the Green in the Blue vs. Red Landscape”).

c) Less Alcohol, More Money and Health

In our October 17, 2024 note “Last Call for Alcohol Companies”, we highlighted a long-term trend suggesting that people are drinking less. In fact, it seems that millennials actually drink less than their X or boomer counterparts, a megatrend which doesn’t bode well for alcoholic beverage makers – but probably better on your wallet and longer-term health prospects.

As a conclusion, the past two years of underperformance of sustainability-themed investment strategies raises a few critical questions for investors who want to change the world with their portfolios – while assuring an acceptable level of performance for their stakeholders.

  1. Sustainable investing is like playing the long game: Are you really ready for it?
  2. Your interest in saving the world from itself through an investor lens may look crazy at times (like now), how much risk are you ready to take in veering away from established benchmarks?
  3. If you agree with our view that climate change and inequalities will be critical economic and increasingly financially material factors over the next 5 years, then financial markets are offering a very attractive opportunity as they are currently anticipating an acceleration of the recent unsustainable past.

For investors that had high hopes that COP29 would deliver some sort of direction about where to allocate capital in a world desperately needing climate solutions, they would be right to be disappointed. Nations failed to agree on binding commitments to phase out fossil fuel subsidies, but perhaps most disappointing relative to expectations is the paltry commitment to emerging economies. The “New Collective Quantified Goal on Climate Finance (NCQG)” was officially drafted and agreed upon during COP29 and earmarks an underwhelming USD 300 billion annually. This sum falls far short of the estimated needs reported by developing countries. Given this modest commitment, it becomes obvious that the role of private finance is critical for a green transition in EM.

In today’s note, we argue why the energy transition in EM will be different than what has occurred so far in developed economies and we outline where we see the most practical opportunities for investors.

 

It’s Different in EM

For developed economies like European countries and the U.S., energy transition means primarily decarbonizing established energy systems by replacing fossil fuel energy sources with renewable ones. In other words, there is a singular objective of energy substitution.

In emerging markets, the energy transition must satisfy multiple goals, sometimes referred to as the energy trilemma: energy security, energy equity (both access and affordability), and energy sustainability. To achieve this, many factors need to be taken into account:

A key point in the energy transition in EMs is that achieving one goal cannot risk sacrificing another. Take the current electricity situation in South Africa. ESKOM is the public utility in South Africa and generates about 95% of electricity for the country and it is also the largest emitter of sulphur dioxide in the power industry in the world. ESKOM has periodically implemented rolling blackouts (a.k.a. load shedding) since 2008, unable to maintain enough power production to consistently meet demand. Ever since, ESKOM has been caught in a death spiral, i.e. a financial and operational catastrophe whereby declining revenues lead to higher costs, which in turn drive more customers away, perpetuating the cycle). Add to this, major governance scandals that make it difficult for ESKOM to attract new capital.

Frustrated by blackouts and rising bills, South Africans that can afford to have invested in private electricity generation (mainly via rooftop solar panels) and therefore have migrated away from Eskom’s grid. This leaves a smaller (and less well-off) base of customers to shoulder ever-rising costs. Faced with fewer (and poorer) consumers and therefore less revenues, ESKOM’s services – reliable electricity output – worsens. In this way, some South Africans that can afford it manage to have access to clean, renewable energy, but those that are left behind see the quality of their (dirty) electricity deteriorate sharply. South Africa may achieve one goal of having a cleaner energy mix through greater use of solar panels, but at the expense of improving energy access to all.

The bottom line is that investors interested in the energy transition in emerging markets are faced with a far more challenging set of variables than in DM. However, the potential for impact is also much higher.

 

Where to Start: An Investors Guide to EM Energy Transition

Investors can have the most impact in countries where access to reliable electricity is weakest. In these regions, clean energy initiatives will offer more than just decarbonization, they will also support improved living standards and economic participation.

Developing nations’ frustrations at the recent COP negotiations is understandable considering the substantial need for investor capital in fund green initiatives. In 2023, only 15% of the $1.8 trillion invested in clean energy infrastructure went to emerging and developing economies according to the World Economic Forum. Moreover, it is estimated that emerging markets will require $2.6 trillion annually for energy investment if 2050 net zero goals are to be achieved. Needless to say, there is a significant funding gap to fill.

Part of the reluctance to fund green energy projects in emerging markets can be explained by the much higher cost of capital. Higher risk premiums are demanded due to a slew of risks (higher volatility in exchange rates, political risks, etc). The chart below highlights the massive range in cost of capital for solar projects in various countries; other renewable energy projects face similar cost of capital ranges.

A Just Transition Means Significantly Higher Cost of Capital

Source: IRENA 

According to the International Agency for Renewable Energy (IRENA), for purposes of energy-transition investments, emerging economies fall into three broad contexts:

Category 1: Countries that already have well-established power markets (e.g.  China, and Brazil). Renewable projects are generally bankable and thus capital costs are lower.

Category 2: Jurisdictions that successfully mobilised large amounts of private capital for certain renewable technologies but are now hitting a ceiling due to technical challenges (e.g. risk of curtailment) or bankability risks (e.g. off-taker risk). Vietnam and South Africa are in this category.

Category 3: Countries that have not been able to attract investments owing to constrained macroeconomic conditions or political conflicts. Projects may not become bankable in the near term, but investments are urgently needed. Even if some projects have already been completed, system integration, transmission constraints, utility creditworthiness are all headwinds. Here, the role of concessional loans and grants and partnering with international organization and/or local government is almost always necessary since investment decisions must be based on factors that go beyond realising financial profits for private investors. Many African countries fit here.

Category 1 economies like China and India experienced a massive growth in energy consumption since 2000, reflecting both demographics and overall economic development over the past 20 years. Electricity consumption per capita increased a whopping 516% in China and 182% in India, far outpacing Africa’s 17% growth. The chart below shows the increased level of energy consumption for industry during this timeframe.

Given that big energy gains have already been achieved, investing in the energy transition in China and to some extent in India, is in many ways like investing in advanced economies: there will be an increasing focus on energy substitution, i.e. decarbonization of current energy systems, rather than building new ones.

Brazil’s slower growth in energy demand reflects its relatively smaller manufacturing sector. The country certainly has an important role to play in lowering emissions; along with China and India, Brazil is among the largest emitters globally. However, its large emissions are far more related to agriculture (nearly 50% of Brazil’s greenhouse gas emissions stem from this sector). Brazil’s heavy reliance on hydroelectricity (see chart further below “Breakdown of Energy Supply by Region”) makes its energy consumption less carbon-intensive compared to other developing nations.  

To be sure, decarbonisation of these countries (category 1) is necessary as the chart above shows that China, India and other BRICs countries (Brazil is an exception) still rely heavily on fossil fuels. However, investors seeking to make greater impact should look to other emerging markets, i.e. countries that are striving to improve access to (renewable) energy, like those in “category three” described above. In frontier markets, particularly Africa, energy needs remain largely unmet. Data from the World Bank shows almost 50% of the population of Sub-Saharan Africa did not have access to electricity in 2022 and still has significantly lower electricity consumption per capita (0.632 MWh) compared to other parts of the world (global electricity per capita is 3.4 MWh). We mentioned earlier the electricity woes of South Africa, yet South Africa has the highest rate of electricity production of African countries.

The following table shows the breakdown of total energy supply by source for various countries and regions. There is plenty of room to expand clean energy in Africa. Notice the high share of biofuel use; this could seem positive, but it is actually a clear example of inequalities in energy access.

The high share of biofuel use comes from the traditional cookstoves that rely on firewood, charcoal and biomass (even animal dung) or high polluting fuels like kerosene. Widespread reliance on cookstoves is a clear consequence of energy poverty and is not only more common in lower-income populations, but also disproportionately affects women and children who have the responsibility of collecting these fuel sources and are also more exposed to the associated pollutants. Cookstoves are used in parts of South Asia and South America but are most common in Africa. Improving accessibility to electricity can facilitate the transition to cleaner cooking technologies.

It is perhaps surprising that nuclear energy is represented in the table above, even at modest shares, in developing economies, given the large capital costs and long pay-off times. Several EMs successfully built nuclear power plants in the 1970s and the 1980s through support from the Soviet Union within the Council for Mutual Economic Cooperation (COMECON) framework or by the United States. Today, however, lack of international cooperation implies that most EMs don’t have the capacity to build reactors. According to the International Atomic Energy Agency (IAEA), only a handful EM countries have any plans at all to invest in nuclear.  

Baby Boomers, defined here as individuals born between 1946 and 1964, represent a pivotal demographic that has significantly shaped global trends. While their population was initially bolstered in regions like North America, Europe, and Australasia by immigration, the effects of aging began to take a noticeable toll globally around the year 2000. Since 2010, their numbers have been declining more sharply as mortality rates have risen—a trend expected to continue for decades.

The evolution of the Baby Boomer population offers insights into changing consumer behavior and societal shifts. Distinct generational experiences influence work attitudes, activism, and consumption patterns today. The table below captures how historical and cultural contexts have molded generational behavior, according to McKinsey.

For instance, Baby Boomers' loyalty to familiar brands contrasts with the more experimental tendencies of younger generations, as seen in the chart below.

This loyalty, however, is not just about habits—it reflects their formative years in a post-war era that emphasized trust and consistency. In the paragraphs below, we illustrate how deeply these values resonate in everyday life. We follow along and observe their consumptions choices for vehicles, travel, news, fashion and entertainment.

 

A Week in the Life of Sir Boomer and Lady Seventy

Day 1: The Road

Sir Boomer woke up early, excited for his upcoming Harley ride along Route 66 with his wife, Lady Seventy. However, their plans were quickly derailed by Boomer’s sudden attack of chest pains. Concerned, his wife quickly drove him in his Jeep Wrangler to the nearest hospital. A mild heart attack was uncovered, and doctors advised against strenuous activities, including motorcycle riding, during his recovery.

Baby boomers have a deep emotional connection with their vehicles, viewing them as symbols of freedom, identity, and adventure. Two emblematic boomer brands are Harley-Davidson motorcycles, which embody their rebellious spirit and love for the open road, and Jeep vehicles, which represent rugged versatility and exploration. For boomers, these brands are more than just modes of transportation.

Stellantis, which owns brands Jeep, Dodge, and Maserati, has relied heavily on Boomers’ loyalty. However, it has faced challenges including recent layoffs at Jeep plants due to lower sales. Similarly, Harley-Davidson is grappling with declining sales and an aging demographic. Younger generations are not engaging with heavyweight motorcycles: while older buyers purchase bikes as a hobby, 21- to 34-year-olds prioritize motorcycles for practical transportation. Polluting bikes and cars are also not attractive for younger consumers.

 

Day 2: The Trip

Boomer and Lady Seventy had planned an Alaskan cruise in May, and look forward to spotting orcas, sea lions, and bears. Though they remain optimistic about making the trip, Boomer's health challenges have forced them to reconsider adventurous outings: future cruise trips may also be uncertain as they adapt to a less physically demanding lifestyle.

Post-pandemic, Baby Boomers have embraced travel as a key retirement activity. These structured travel experiences align with their preference for scenic and well-organized adventures. Baby Boomers also spend significantly more on accommodations than younger generations; their budget is often more than double that of Millennials.

Cruise lines like Royal Caribbean and Carnival Cruises, which have flourished in recent years, face demographic headwinds from their primary clientele, Baby Boomers. According to industry data, the average age of a cruise passenger is 55! While the sector has enjoyed strong demand with high occupancy rates, its reliance on an aging customer base suggests potential difficulties in sustaining growth. Moreover, cruise lines are pollution raft with large fuel consumption and heavy plastic use.

Day 3: A Reflection on Past Vacations

The shock from his health issues is really affecting Sir Boomer. He recalled that on a recent trip to Arubahe sometimes felt a out of breath, but didn’t realize it signaled something major. He and his wife purchased their time share package five years ago, believing they would easily spend a month per year there for at least 20 years. Would they be able to stick to this plan?

Companies like Travel and Leisure and Hilton Grand Vacations, which depend heavily on the time share model, face challenges in capturing new audiences. Millennials and Gen Z are more attracted to unique travel experiences and flexible options such as Airbnb: 60% of guests who have booked on Airbnb are millennials. From a sustainability perspective, the pressure tactics of time shares are not an attractive feature.

Day 4: The News

On Thursday, Boomer was discharged from the hospital and returned home. He immediately turned on the TV in the garage, his favorite spot for tinkering while catching up on Fox News. The couple still has four televisions, even though their kids have long left the house. His wife turns the kitchen TV on; she watches MSNBC.

Boomers predominantly consume traditional media, such as cable TV, radio, and print newspapers. For Millennials and Gen Z, the landscape is vastly different:  streaming services like Netflix and Spotify dominate their consumption. This shift to streaming media as a news source marks a significant transformation in viewing behavior. The growing time spent on social media signals a paradigm shift in content consumption, with younger generations gravitating toward short-form, engaging content on these platforms.

These generational differences are shaping media and entertainment. Five years ago, the median age of a Fox News viewer was 65. It is true that Fox Corporation is more than news; it also covers sports and entertainment. Nonetheless, it will have to renew its viewership. Comcast, which owns NBC, is in a similar predicament, although it also owns Universal Pictures, theme parks, the Peacock streaming service and other telecommunication assets, The company’s revenues are mainly derived from older people. On top of that, the partisan politics of the traditional chains are affecting the confidence in the media of the population.

Day 5: The Entertainment

After all the emotions of the last few days, Boomer and Lady Seventy decide to heed the doctor’s orders with some relaxation. They watch the movie, “Risky Business”, for a bit of nostalgia. Boomer says: “They don’t make movies like this anymore, now it’s just animation and superheroes”.  Together, they reminisce and hum the movie’s best song “In the Air Tonight” by Phil Collins.

Both Paramount Pictures and Universal Music Group must adapt to evolving consumer preferences as the Baby Boomer generation ages. Paramount, for instance, recently announced layoffs and the closure of its Paramount Television Studios, citing significant challenges in the TV and streaming marketplace. With streaming platforms also disrupting traditional box office revenues, Paramount’s reliance on legacy content and cable programming fees is no longer sustainable.

Similarly, Universal Music Group faces headwinds as streaming revenue growth fell short of expectations, leading to a 30% drop in its stock value in July 2024. The company has also encountered challenges on platforms like TikTok, where a contractual dispute resulted in the removal of Universal’s music, potentially limiting its artists' reach among younger audiences. As digital disruption accelerates, both Paramount and Universal risk losing relevance in an increasingly competitive entertainment landscape.

Day 6: The Memories

It’s now Friday, Boomer’s health is improving, and the couple decides to go out to eat. As usual, they plan to dress for the event: Levi jeans and a Polo shirt; the preppy look of the 1980’s and early 1990’s influenced by movies like The Breakfast Club and Risky Business. A Polo and Levi’s was trendy back then, and it’s still the case for Lady Seventy and Sir Boomer.

Fashion trends reflect generational contrasts. Boomers continue to prioritize durable, timeless styles, whereas Millennials and Gen Z embrace rapid trend cycles fueled by social media. Brands like Brandy Melville, Dickies, and emerging designer labels resonate with Gen Z’s aesthetic, while vintage shopping and flea markets are also central to their fashion habits. Gen Z and Millennials exhibit a mix of priorities, often claiming to support sustainability while embracing fast fashion brands for their affordability and trendy appeal—choices that raise concerns about environmental and ethical impacts.

While Baby Boomers historically supported preppy brands like Ralph Lauren and Levi Strauss, these companies now face challenges as consumer trends evolve. Some 90s brands, such as Abercrombie, are experiencing a resurgence, but the fickle nature of fashion consumers means staying relevant requires constant adaptation. Millennials and Gen Z increasingly prioritize sustainability, affordability, and fast-changing trends, making it difficult for traditional brands to maintain their edge without significant reinvention.

Day 7: The Night Out

Their last decision is where to go? Cracker Barrel or Olive Garden. They end up choosing Cracker Barrel for its wider menu so that Sir Boomer can choose a healthier meal.

Dining habits reflect distinct generational values and constraints. Interestingly, over 70% of younger generations integrate restaurant-prepared items into home meals.

Takeout and delivery are essential to younger consumers, with most relying on third-party platforms. By contrast, Boomers are less likely to use delivery services. Baby Boomers remain loyal to legacy restaurant chains, valuing consistency, nostalgia, and familiarity. Restaurants catering primarily to Boomers, like Cracker Barrel (43% of customers aged 55+ in 2023) and groups like Darden Restaurants, risk losing market share unless they adapt to these changing preferences.

Sir Boomer and Lady Seventy: Portfolio Choices

During dinner, Sir Boomer and Lady Seventy discussed their investment portfolios, which reflect their philosophy of investing in familiar companies. This approach has served them well, though recently their returns have lagged behind market benchmarks.

As the table below shows, Sir Boomer’s companies generally have decent margins and relatively low Price to Earnings (PE) ratios reflecting their low growth potential. However, we expect profit margins to shrink alongside declining sales due to a combination of increased competition, rising input costs, and the challenge of adapting products to a shrinking target demographic.

The table below shows that Lady Seventy’s companies have a similar profile. Investing in things you use and understand may have made sense when they were part of the most important purchasing generation; baby boomers were a much larger generation than all previous generations and they out-earned their parents during all time periods of their lives. But Boomers are no longer the most important purchasing group, having been surpassed by Millennials.

The next two charts show the performance of their respective holdings over the past two years. Of the 14 companies, only three—Royal Caribbean, Carnival, and Ralph Lauren—have outperformed the S&P 500. While these companies are currently performing well, they face structural challenges. For cruise operators, high occupancy rates are driven by a wealthy client base and strong Boomer demand. However, as Boomers age and reduce travel, these trends are likely unsustainable. Similarly, Ralph Lauren benefits from affluent customers but must contend with shifting consumer preferences toward sustainable and inclusive fashion, which could erode its competitive edge in the long run. The other eleven companies that have underperformed, do not target affluent individuals which may explain some of the difference in results compared to the cruise lines and Ralph Lauren. Affluent customers, often wealthy retirees, are less affected by tighter budgets and economic uncertainties, allowing them to sustain discretionary spending on premium goods and services. However, we believe even companies targeting wealthy customers are on borrowed time, as demographic shifts make it increasingly difficult to meet the high expectations placed on them.

The election of Donald Trump has cast a pall over many investors that adhere to the idea that purchasing stocks using both financial and non-financial criteria deliver superior long-term returns.

To be sure, the turn away from “ESG” investing has been underway for quite some time – the chart below shows that fund outflows from U.S. ESG ETFs occurred throughout 2023 and 2024.

President-elect Donald Trump will most likely move to dismantle ESG-related regulations in the U.S. when he takes office in January, including blocking Securities and Exchange Commission rules for corporate and fund disclosures and putting limits on ESG-related shareholder proposals filed during proxy season. U.S. companies have already taken the hint that ESG is no longer a sales or marketing advantage and have been working fast to erase the phrase “ESG” from corporate speak: the chart below shows the precipitous drop-off of the number of mentions during quarterly earnings calls.

The turn away from ESG is not, however, a death knell for investors that focus on sustainability. Investors should recall that Trump’s first term was an excellent time for many thematic sustainability funds and many equity sectors moved in a contrary fashion to consensus expectations:

The key takeaway is that despite the anti-ESG trend, successful investing remains about understanding the macroeconomic backdrop and anticipating the needs and desires of the future. As climate change and related environmental challenges continue to mount at a time when social inequalities are ever-present, sustainability themes will not fade from focus.

That said, President-elect Trump’s policy aims will nonetheless shift the macroeconomic backdrop in ways that impact key sustainability themes. In today’s note, we outline how inflation, industrial policy and climate change will affect the outlook for these themes.

  1. Inflation: Yes. But Where and How Much?

It has become a consensus view that a Trump presidency will exacerbate inflation. We find it difficult to disagree. After all, economic theory, borne out in practice time and again, shows us that large fiscal deficits (which are expected thanks to the extension of tax cuts under Trump) stoke inflation. Tariffs are also inflationary – historically, about half of the cost of tariffs is assumed by producers (via smaller profit margins) and the other half by consumers (rising prices).

Pile on a restrictive immigration policy that will further constrain an already cyclically and structurally tight labor market and labor costs will face upward pressure, all else equal.

Nowhere will the labor squeeze be felt more acutely than in agriculture and our forecast is that food prices are the most likely source of consumer price inflation in the intermediate term. A recent article in the Atlantic estimated that if the Trump administration were to enact “the largest deportation operation in American history, somewhere between 40 and 50 percent of the people who plant U.S. crops would leave the domestic workforce.”

Already, food inflation has been running hotter than overall CPI due to structural reasons: the global population is projected to increase by 10% this decade while the lower and upper-middle-class increase by 30%. As more people reach the middle class and adopt a more calorific diet as is characteristic of that class, the demand for food will continue to increase. Meanwhile, on the supply side, it is unlikely that more of the earth’s land surface can be dedicated to food production and climate change is also complexifying food production as we know it.

Though the nomination of Robert F. Kennedy Junior as Secretary of the Department of Health and Human Services (HHS) is not yet a done deal (RFK Jr’s aberrant views on vaccines, fluoride, cell phone radiation and other topics mean that many groups are already lobbying against his nomination); when it comes to food, RFK’s desired policy path would unequivocally result in higher food price inflation. The current U.S. food system is designed to maximize yields at the lowest cost. An overhaul that includes solving for multiple variables, i.e. improving human health and environmental outcomes, will not come without financial cost for consumers.  

At Sustainable Market Strategies, we have high conviction that sustainable food production will be an important investment theme over the next decade (for example, please see our note “Food for Thought”, September 21, 2023). Readers can expect updated research from us, especially should RFK be nominated. Investors should closely watch the policy backdrop for opportunities on both the long and short side within the food and health sectors.

  1. Industrial Economy 2.0: Bring the Companies Home

We have written extensively over the past several years about the rising dominance of fiscal policy that has occurred since 2010. Notably, in 2021, we quoted ex-Fed Chairman Ben Bernanke, who, after dropping the Federal interest rate to zero and undertaking the largest quantitative easing program in history, declared, “The Federal Reserve cannot solve all the economy's problems on its own.” He subsequently called on Congress, the administration, and regulators to do more to prop up the U.S. economy. Washington policymakers jumped to the call and have never looked back. Since that time, both Republican and Democrat governments have announced major fiscal packages that have totaled over 9 trillion USD. In the table below, we list, describe and colour-code (features in red denote fiscal measures targeting specific industries) the main features of the various spending bills. A pattern emerges: spending packages are increasingly being used to deploy industrial policy.

Investors may recall that soon after Biden was elected, the White House published a list of key priorities for the government (see the table below). These priorities were reflected in the spending bills of the past four years, and to a great extent (the proliferation of AI notwithstanding) were apparent in the growth prospects and stock performance of U.S. companies.

There is a strong consensus that at the top of Trump’s priority list is the reshoring of U.S. manufacturing as well as other key industries critical to national security and autonomy (e.g. energy and semiconductors).

To be sure, manufacturing re-shoring and rebuilding should be viewed as a continuation of a trend that got underway with the Inflation Reduction Act, since the bill inherently favored onshoring jobs and production in key sectors. In this sense, many of the excelling companies that have benefited from the process of “deglobalization,” i.e. the building out of domestic supply chains, will continue to thrive in the years ahead. Sustainability focused investors should look for industrial companies with most of their revenues in the U.S. and that support resource efficiency, climate adaptation, automation as these will be in high demand, some of which are highlighted in the table below.

 

  1. Investors Must Make Room for Climate Change Adaptation

Should the U.S. withdraw from the Paris Agreement - as is most likely under Trump – there are lower odds that the planet will warm at less than two degrees in the coming decades.

A study by McKinsey found that even if the global temperature warms only by 1.5°C by 2030 –an increasingly elusive target as we drag our feet on concrete actions – almost half of the world's population will still be exposed to climate hazards, such as heat stress, drought and floods. On this basis, it makes sense for investors to make greater space in their portfolios for companies focused on climate change adaptation.

As it stands, climate adaptation is mitigation’s poor little brother when it comes to financing, with 93% of total climate funding going towards reducing greenhouse gas emissions instead of building resilient infrastructure.

President-elect Trump’s distaste for global cooperation on climate change implies that investors should now be looking for opportunities beyond mitigation. The climate adaptation trade can take many forms, from betting on the long-term success of the most prepared insurance companies to banking on the increased demand for data from firms that feed insurance models, to positioning for increased spending on resilient infrastructure.